...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Young Pharmacists >Comparison of Insulin, Sulfonylurea and Sulfonylureas-Metformin Combination on HbA1c and eGFR Level on Age-, Sex- and BMI-Matched Groups of Indonesian Type 2 DM Patients
【24h】

Comparison of Insulin, Sulfonylurea and Sulfonylureas-Metformin Combination on HbA1c and eGFR Level on Age-, Sex- and BMI-Matched Groups of Indonesian Type 2 DM Patients

机译：印尼2型糖尿病患者年龄，性别和体重指数匹配人群胰岛素，磺脲类和磺脲类-二甲双胍联合用药对HbA1c和eGFR水平的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: This study aimed to evaluate efficacy of insulin, sulfonylurea, and sulfonylureas-metformin combination in reducing the HbA1c level and preventing renal function decline in type 2 diabetes mellitus (DM) patients in Indonesia. Methods: A cross-sectional study was conducted at Dr. Sitanala Hospital involving 105 patients who were taking: insulin (30), sulfonylureas (30) and sulfonylureas-metformin combination (45). The subjects were classified into age-, sex- and BMI-matched groups. We measured their HbA1c level and serum creatinine to calculate eGFR level. Results: There were no differences among the three groups in term of age, sex, BMI, occupation and exercise habit. However, diet and family history of DM were different between the three groups. The average of HbA1c levels in the sulfonylureas-metformin group was 7.46±1.81 and showed a significant difference compared to the insulin group (8.27±1.74) with p=0.042. No significant difference existed in eGFR in the three groups (p=0.476). Subjects with obesity or BMI 30 kg/m2 had 3.268 times probability (p= 0.001) of having HbA1c 7 relative to underweight (BMI 2), after adjustment for comorbidity, diet and exercise habit. Subjects with diabetic family history had 1.616 times relative risk to have HbA1c level 7%, compared to those without diabetic family history (p = 0.002). Conclusion: We found in this study site that sulfonylureas-metformin combination was more efficient in decreasing HbA1c level in type 2 DM patients compared to insulin or sulfonylureas monotherapy. Family history of DM and overweight had considerable effect on uncontrolled HbA1c. Meanwhile, there was no significant difference among the three groups in preventing the decline of eGFR.
机译：目的：本研究旨在评估胰岛素，磺酰脲类和磺酰脲类-二甲双胍组合在降低印度尼西亚2型糖尿病（DM）患者HbA1c水平和预防肾功能下降中的功效。方法：在西塔纳拉医生医院进行了一项横断面研究，涉及105位正在服用的患者：胰岛素（30），磺酰脲类（30）和磺酰脲-二甲双胍联合用药（45）。将受试者分为年龄，性别和BMI匹配组。我们测量了他们的HbA1c水平和血清肌酐，以计算eGFR水平。结果：三组在年龄，性别，BMI，职业和运动习惯方面均无差异。但是，三组之间的饮食和糖尿病家族史不同。磺酰脲类-二甲双胍组的HbA1c水平平均值为7.46±1.81，与胰岛素组相比，差异有统计学意义（8.27±1.74），p = 0.042。三组的eGFR无显着差异（p = 0.476）。调整合并症，饮食和运动习惯后，肥胖或BMI> 30 kg / m2的受试者相对于体重不足（BMI 2）的HbA1c> 7的可能性为3.268倍（p = 0.001）。与没有糖尿病家族史的受试者相比，具有糖尿病家族史的受试者的HbA1c水平> 7％的相对风险为1.616倍（p = 0.002）。结论：我们在该研究地点发现，与胰岛素或磺酰脲类单一疗法相比，磺酰脲类-二甲双胍联合治疗2型DM患者降低HbA1c水平更有效。 DM的家族史和超重对不受控制的HbA1c有相当大的影响。同时，三组在预防eGFR下降方面无显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号